Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat ...
Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...
News-Medical.Net on MSN9d
BIOVECTRA is honored with 2025 CDMO Leadership Award for biologicsBIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics ...
SAN DIEGO — Across six asthma biologics, adherence differed by the ... This cross-sectional cohort study was presented at the 2025 American Academy of Allergy, Asthma and Immunology/World ...
ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results